AIM ImmunoTech
16 hedge funds and large institutions have $5.35M invested in AIM ImmunoTech in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
146% more capital invested
Capital invested by funds: $2.18M → $5.35M (+$3.17M)
33% more funds holding
Funds holding: 12 → 16 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$656K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$402K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$106K |
| 4 |
Millennium Management
New York
|
+$106K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$139K |
| 2 |
Renaissance Technologies
New York
|
-$30K |
| 3 |
Goldman Sachs
New York
|
-$6K |
AIM Hedge Fund Activity: Q1 2014 in Review
16 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2014, worth a combined $5.35M — up 146% from $2.18M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AIM positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock Institutional Trust, adding an estimated $656K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $139K sold.
- 16 institutional investors held AIM ImmunoTech (AIM) as of Q1 2014, up from 12 in Q4 2013.
- Funds reported $5.35M of AIM ImmunoTech stock for Q1 2014, up 146% quarter-over-quarter.
- 6 funds opened new AIM ImmunoTech positions in Q1 2014 and 2 closed out, a net change of +4 holders.
- The largest AIM ImmunoTech buyer in Q1 2014 was BlackRock Institutional Trust, an estimated $656K added.
- The largest AIM ImmunoTech seller in Q1 2014 was Jacobs Levy Equity Management, an estimated $139K sold.
Based on aggregated 13F filings for Q1 2014.